KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) Return on Sales (2016 - 2025)

Pacira BioSciences has reported Return on Sales over the past 16 years, most recently at 0.01% for Q4 2025.

  • Quarterly results put Return on Sales at 0.01% for Q4 2025, down 8.0% from a year ago — trailing twelve months through Dec 2025 was 0.01% (up 15.0% YoY), and the annual figure for FY2025 was 0.01%, up 15.0%.
  • Return on Sales for Q4 2025 was 0.01% at Pacira BioSciences, down from 0.03% in the prior quarter.
  • Over the last five years, Return on Sales for PCRX hit a ceiling of 0.15% in Q2 2023 and a floor of 0.85% in Q3 2024.
  • Median Return on Sales over the past 5 years was 0.05% (2022), compared with a mean of 0.01%.
  • Biggest five-year swings in Return on Sales: plummeted -97bps in 2021 and later surged 88bps in 2025.
  • Pacira BioSciences' Return on Sales stood at 0.03% in 2021, then surged by 164bps to 0.02% in 2022, then surged by 569bps to 0.14% in 2023, then plummeted by -38bps to 0.09% in 2024, then crashed by -90bps to 0.01% in 2025.
  • The last three reported values for Return on Sales were 0.01% (Q4 2025), 0.03% (Q3 2025), and 0.03% (Q2 2025) per Business Quant data.